RSS-Feed abonnieren

DOI: 10.1055/a-2692-3064
Clinical Characteristics and Prognosis of Sepsis Subphenotypes Identified by Coagulation Indicator Trajectories: A Single-Center Retrospective Study
Funding Information This study was supported by the National Key R&D Program of China (number: 2022YFC2304601), CAMS Innovation Fund for Medical Sciences (CIFMS) from Chinese Academy of Medical Sciences (2021-I2M-1-062), National Key Clinical Specialty Construction Projects from National Health Commission, National Key R&D Program of China from Ministry of Science and Technology of the People's Republic of China (number: 2021YFC2500801).

Abstract
Background
This study aimed to identify new sepsis subphenotypes on the basis of coagulation indicator trajectories and comprise clinical characteristics and prognosis.
Patients and Methods
This retrospective study included patients diagnosed with sepsis admitted to the intensive care unit of Peking Union Medical College Hospital from May 2016 to March 2023. Using group-based trajectory models, we classified patients into different subphenotypes on the basis of the dynamic daily changes in coagulation parameters within the first 7 days after sepsis diagnosis. Clinical characteristics and outcomes of patients were compared between subphenotypes.
Results
A total of 3,990 patients diagnosed with sepsis were included in this research. Patients were divided into four trajectory groups on the basis of indicator trajectory: Group 1 (n = 500), with high prothrombin times (PTs) and rapidly increasing D-dimer levels; Group 2 (n = 1,334) had normal PT, mildly increasing D-dimer levels and platelet counts. Group 3 (n = 1,013), with mildly elevated PT and D-dimer levels, along with lower platelet counts and fibrinogen levels. Group 4 (n = 1,143) had mildly elevated PT and D-dimer levels along with elevated platelet and fibrinogen levels. Four trajectory subphenotypes exhibit different 28-day mortality, overall in-hospital mortality, bleeding and thrombosis incidence, and the rate of patients with mechanical ventilation.
Conclusion
Coagulation trajectory subphenotypes offer a novel approach for stratifying sepsis heterogeneity, identifying high-risk patients, and refining prognostic assessment. The subphenotype with rapidly rising D-dimer levels warrants heightened clinical vigilance due to its association with the poorest outcomes.
Keywords
sepsis - subphenotype - disseminated intravascular coagulation - D-dimer - group-based trajectory modelsData Availability Statement
The data utilized in this study can be accessed by the corresponding author on reasonable request.
Contributors' Statement
All the authors participated in the conceptualization and design of the study. Data collection and analysis, as well as the writing of the manuscript, were completed by B.Y.W. All the authors were involved in the research process and the revision of the manuscript. All the authors have read the final draft and agreed to its publication.
Ethics Approval
This study received approval from the Institutional Review Board at Peking Union Medical College Hospital. The approval included a waiver for the informed consent of the patients.
Publikationsverlauf
Eingereicht: 22. März 2025
Angenommen: 26. August 2025
Artikel online veröffentlicht:
09. September 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Singer M, Deutschman CS, Seymour CW. et al. The Third International Consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315 (08) 801-810
- 2 Rudd KE, Johnson SC, Agesa KM. et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 2020; 395 (10219): 200-211
- 3 Rhee C, Dantes R, Epstein L. et al; CDC Prevention Epicenter Program. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA 2017; 318 (13) 1241-1249
- 4 Kheterpal S, Singh K, Topol EJ. Digitising the prediction and management of sepsis. Lancet 2022; 399 (10334): 1459
- 5 Santacroce E, D'Angerio M, Ciobanu AL. et al. Advances and challenges in sepsis management: modern tools and future directions. Cells 2024; 13 (05) 439
- 6 Bhavani SV, Semler M, Qian ET. et al. Development and validation of novel sepsis subphenotypes using trajectories of vital signs. Intensive Care Med 2022; 48 (11) 1582-1592
- 7 Xu Z, Mao C, Su C. et al. Sepsis subphenotyping based on organ dysfunction trajectory. Crit Care 2022; 26 (01) 197
- 8 Bhavani SV, Carey KA, Gilbert ER, Afshar M, Verhoef PA, Churpek MM. Identifying novel sepsis subphenotypes using temperature trajectories. Am J Respir Crit Care Med 2019; 200 (03) 327-335
- 9 Leng F, Gu Z, Pan S. et al. Novel cortisol trajectory sub-phenotypes in sepsis. Crit Care 2024; 28 (01) 290
- 10 Ye Q, Wang X, Xu X. et al. Serial platelet count as a dynamic prediction marker of hospital mortality among septic patients. Burns Trauma 2024; 12: tkae016
- 11 Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Intensive Care Med 2004; 30 (06) 1032-1040
- 12 Iba T, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Anesthesiology 2020; 132 (05) 1238-1245
- 13 Ding R, Wang Z, Lin Y, Liu B, Zhang Z, Ma X. Comparison of a new criteria for sepsis-induced coagulopathy and International Society on Thrombosis and Haemostasis disseminated intravascular coagulation score in critically ill patients with sepsis 3.0: a retrospective study. Blood Coagul Fibrinolysis 2018; 29 (06) 551-558
- 14 Iba T, Helms J, Connors JM, Levy JH. The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation. J Intensive Care 2023; 11 (01) 24
- 15 Nagin DS, Jones BL, Elmer J. Recent advances in group-based trajectory modeling for clinical research. Annu Rev Clin Psychol 2024; 20 (01) 285-305
- 16 Giustozzi M, Ehrlinder H, Bongiovanni D. et al. Coagulopathy and sepsis: pathophysiology, clinical manifestations and treatment. Blood Rev 2021; 50: 100864
- 17 Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost 2020; 46 (01) 89-95
- 18 Lelubre C, Vincent JL. Mechanisms and treatment of organ failure in sepsis. Nat Rev Nephrol 2018; 14 (07) 417-427
- 19 Iba T, Umemura Y, Wada H, Levy JH. Roles of coagulation abnormalities and microthrombosis in sepsis: pathophysiology, diagnosis, and treatment. Arch Med Res 2021; 52 (08) 788-797
- 20 Taylor Jr FB, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86 (05) 1327-1330
- 21 Gando S, Meziani F, Levi M. What's new in the diagnostic criteria of disseminated intravascular coagulation?. Intensive Care Med 2016; 42 (06) 1062-1064
- 22 Dhainaut JF, Yan SB, Joyce DE. et al. Treatment effects of Drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004; 2 (11) 1924-1933
- 23 Gando S, Iba T, Eguchi Y. et al; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006; 34 (03) 625-631
- 24 Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open 2017; 7 (09) e017046
- 25 Umemura Y, Yamakawa K, Hayakawa M, Hamasaki T, Fujimi S. Japan Septic Disseminated Intravascular Coagulation (J-Septic DIC) study group. Screening itself for disseminated intravascular coagulation may reduce mortality in sepsis: a nationwide multicenter registry in Japan. Thromb Res 2018; 161: 60-66
- 26 Wiedermann CJ. Antithrombin concentrate use in disseminated intravascular coagulation of sepsis: meta-analyses revisited. J Thromb Haemost 2018; 16 (03) 455-457
- 27 Kudo D, Goto T, Uchimido R. et al. Coagulation phenotypes in sepsis and effects of recombinant human thrombomodulin: an analysis of three multicentre observational studies. Crit Care 2021; 25 (01) 114
- 28 Wang K, Lu D, Wang F. Subphenotypes of platelet count trajectories in sepsis from multi-center ICU data. Sci Rep 2024; 14 (01) 20187
- 29 Wang Y, Wu J, Shao T. et al. Prognostic implications of changes in platelet trajectories in patients with sepsis: a retrospective analysis using the medical information mart for intensive care-IV database. Shock 2024;
- 30 Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol 2017; 70 (19) 2411-2420
- 31 Rodelo JR, De la Rosa G, Valencia ML. et al. D-dimer is a significant prognostic factor in patients with suspected infection and sepsis. Am J Emerg Med 2012; 30 (09) 1991-1999
- 32 Han YQ, Yan L, Zhang L. et al. Performance of D-dimer for predicting sepsis mortality in the intensive care unit. Biochem Med (Zagreb) 2021; 31 (02) 020709
- 33 Semeraro F, Ammollo CT, Caironi P. et al. Low D-dimer levels in sepsis: good or bad?. Thromb Res 2019; 174: 13-15
- 34 Chistolini A, Ruberto F, Alessandri F. et al; Policlinico Umberto I COVID-19 Group. Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19. Br J Haematol 2020; 190 (04) e214-e218